phenyl acetate has been researched along with Focal Nodular Hyperplasia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernardi, M; Boschi, S; Colecchia, A; Fanti, S; Farsad, M; Feletti, V; Franchi, R; Frigerio, M; Golfieri, R; Jovine, E; Lodi, F; Magini, G; Patti, C; Serra, C; Trevisani, F; Vivarelli, M | 1 |
| Dang, Y; Fu, Z; Huo, L; Wu, Z; Zhuang, H | 1 |
2 other study(ies) available for phenyl acetate and Focal Nodular Hyperplasia
| Article | Year |
|---|---|
C-11 acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma.
Topics: Acetates; Adenoma, Liver Cell; Adolescent; Adult; Aged; Aged, 80 and over; Carbon; Carbon Isotopes; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Focal Nodular Hyperplasia; Humans; Liver Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Young Adult | 2009 |
Dual time point C-11 acetate PET imaging can potentially distinguish focal nodular hyperplasia from primary hepatocellular carcinoma.
Topics: Acetates; Carbon; Carcinoma, Hepatocellular; Diagnosis, Differential; Feasibility Studies; Focal Nodular Hyperplasia; Humans; Liver Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity | 2009 |